Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment

American Journal of Translational Research

Volumn 4, Issue 1, 2012, Pages 14-23

  Kong, Dejuan ^a   Heath, Elisabeth ^a   Chen, Wei ^a   Cher, Michael ^a   Powell, Isaac ^a   Heilbrun, Lance ^a   Li, Yiwei ^a   Ali, Shadan ^a   Sethi, Seema ^b   Hassan, Oudai ^b   Hwang, Clara ^b   Gupta, Nilesh ^b   Chitale, Dhananjay ^b   Sakr, Wael A ^b   Menon, Mani ^b   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Androgen receptor (AR); BR DIM; Methylation; miR 34a; PSA

Indexed keywords

3,3' DIINDOLYLMETHANE; 5 AZA 2' DEOXYCYTIDINE; ANDROGEN RECEPTOR; MICRORNA; MICRORNA 34A; NOTCH1 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL; CANCER GRADING; CELL STRAIN LNCAP; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; EPIGENETICS; GENE LOSS; GENE SILENCING; GENETIC TRANSFECTION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84863050461     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormonerefractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int 2005; 95: 1320-1326.
3. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, Wilson EM and French FS. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-448.
4. Agoulnik IU, Weigel NL. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 2006; 99: 362-372.
5. Ostling P, Leivonen SK, Aakula A, Kohonen P, Makela R, Hagman Z, Edsjo A, Kangaspeska S, Edgren H, Nicorici D, Bjartell A, Ceder Y, Perala M and Kallioniemi O. Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Res 2011; 71: 1956-1967.
6. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17: 193-199.
7. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J and Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-2600.
8. Li WB, Ma MW, Dong LJ, Wang F, Chen LX and Li XR. MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme. Cancer Biol Ther 2011; 12: 477-483.
9. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D and Tang DG. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17: 211-215.
10. Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S and Sarkar FH. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormonesensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006; 66: 10064-10072.
11. Kong D, Li Y, Wang Z, Banerjee S and Sarkar FH. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007; 67: 3310-3319.
12. Kong D, Banerjee S, Huang W, Li Y, Wang Z, Kim HR and Sarkar FH. Mammalian target of rapamycin repression by 3,3'-diindolylmethane inhibits invasion and angiogenesis in plateletderived growth factor-D-overexpressing PC3 cells. Cancer Res 2008; 68: 1927-1934.
13. Heath EI, Heilbrun LK, Li J, Vaishampayan U, Harper F, Pemberton P and Sarkar FH. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate- resistant, non-metastatic prostate cancer. Am J Transl Res 2010; 2: 402-411.
14. Kong D, Li Y, Wang Z, Banerjee S, Ahmad A, Kim HR and Sarkar FH. miR-200 Regulates PDGF-D-Mediated Epithelial-Mesenchymal Transition, Adhesion, and Invasion of Prostate Cancer Cells. Stem Cells 2009; 27: 1712-1721.
15. Fleischmann A, Rocha C, Schobinger S, Seiler R, Wiese B and Thalmann GN. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. Prostate 2011; 71: 453-460.
16. Li Y, Wang Z, Kong D, Murthy S, Dou QP, Sheng S, Reddy GP and Sarkar FH. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 2007; 282: 21542-21550.
17. Sarkar FH, Li Y. Cell signaling pathways altered by natural chemopreventive agents. Mutat Res 2004; 555: 53-64.
18. Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA and Sarkar FH. Up-regulation of miR- 200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712.
19. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F and Esteller M. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2011.
20. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, Tessema M, Leng S and Belinsky SA. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 2011; 71: 3087-3097.